Last reviewed · How we verify
OT-101 Ophthalmic Solution
OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye.
OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye. Used for Corneal neovascularization and scarring, Alkali burn of the eye.
At a glance
| Generic name | OT-101 Ophthalmic Solution |
|---|---|
| Also known as | Investigational Product |
| Sponsor | Ocumension (Hong Kong) Limited |
| Drug class | Wnt/β-catenin signaling inhibitor |
| Target | Wnt/β-catenin pathway |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
OT-101 targets the Wnt signaling pathway, which plays a key role in pathological corneal neovascularization and fibrosis. By inhibiting this pathway, the drug aims to suppress abnormal blood vessel growth and reduce inflammatory responses in corneal diseases. This mechanism is particularly relevant for conditions characterized by corneal scarring and vision loss due to neovascularization.
Approved indications
- Corneal neovascularization and scarring
- Alkali burn of the eye
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- Study of OT-101 in Treating Myopia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |